What is it about?

Methicillin-resistant Staphylococcus aureus (MRSA) is commonly treated with vancomycin. During prolonged therapy, however, MRSA can become less susceptible to vancomycin, and this change may also reduce the activity of other antibiotics that act on the bacterial cell wall or membrane. In this laboratory study we exposed MRSA strains to vancomycin to select less susceptible variants, and then tested how well two alternative drugs, telavancin and daptomycin, still worked against them.

Featured Image

Why is it important?

When vancomycin fails, clinicians need to know which alternative antibiotics remain reliable. Laboratory data on cross-reduced susceptibility help guide the choice of salvage therapy for difficult MRSA infections such as bacteraemia and endocarditis.

Perspectives

This was one of my first experiences in the microbiology laboratory, and it taught me how much the behaviour of bacteria under antibiotic pressure can tell us about what happens in our patients during long treatments.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: Telavancin and daptomycin activity against meticillin-resistant Staphylococcus aureus strains after vancomycin-resistance selection in vitro, Journal of Medical Microbiology, April 2013, Society for General Microbiology,
DOI: 10.1099/jmm.0.060640-0.
You can read the full text:

Read

Contributors

The following have contributed to this page